It describes the components and methods of drugs used to treat viral infection, hypercholesterolemia, hyperglycemia, Alzheimer's disease, congenital diseases and lymphocyte atrophy, as well as the methods of treatment with oligonucleotide adhesive. Claim 6: the pharmaceutical formulation of any category 1-5 claim in which the oligonucleotide is thinned with different metal cations. 115. Claim 11: description of any 1-5 claims for drugs, wherein the oligonucleotides claimed include calcium and magnesium. Claim 12: any drug formulation of claims 1-5,The oligonucleotides mentioned here include at least one second-line oligonucleotide. 113. Claim 13: any 1-5 claimed pharmaceutical formulation, wherein the said oligonucleotide comprises at least one oligonucleotide and at least one phosphoconjugation. 115. Claim 15: any pharmaceutical formulation of claims 1-5, wherein said oligonucleotide includes at least one oligonucleotide, as amended in Item 2. Claim 16: any drug formulation of claims 1-5,The oligonucleotides described here have at least one oligonucleotide, each river in the 2 or methyl position. 109. Claim 18: for any one claim in claims 1-5, the said oligoribonucleic acid includes at least one oligonucleoside, each of which is 5methicitosin. Claim 21: a pharmaceutical formulation comprising a binder for SEQ ID 20 for the treatment of high cholesterol. 11. Claim 22: a pharmaceutical preparation including Chemical Abstracts Service No. 19 for treatment.Duchamp's muscular dystrophy. Claim 23: medicament claim 24 with adhesive No. 7 SEQ ID for the treatment of hepatitis C infection: description of any 1-5 and 21-23 claimsHere, the oligoribonucleic acid is designed for a hypodermic administration. Claim 25: drug expression for any one of 1-5 and 21-23, i.e. the oligonucleotide condensate is used for injection.Se describen composiciones farmacéuticas y métodos para el tratamiento de infecciones virales, hipercolesterolemia, hipertrigliceridemia, Alzheimer, enfermedades
